Neuphoria Confirms Merger Talks with Scancell as UK Biotech Eyes Nasdaq Listing
Key Insights
Neuphoria Therapeutics (search) confirmed it is in discussions with Scancell Holdings (search) about a potential acquisition that would result in Scancell becoming a Nasdaq-listed company.
The deal comes as Neuphoria conducts a strategic review following the failure of its Phase III AFFIRM-1 trial of BNC210 in social anxiety disorder (search).
Scancell seeks Nasdaq access to attract specialist biotech investors as it prepares for a pivotal Phase III study of its lead cancer immunotherapy, iSCIB1+ (search), for advanced melanoma (search).
Neuphoria Therapeutics (search) Inc. (NASDAQ: NEUP) confirmed on June 26, 2026, that it is in discussions with London-listed Scancell Holdings (search) plc about a potential acquisition that would see Scancell become a Nasdaq-listed company upon closing. The announcement came in response to an earlier statement by Scancell, which was made following speculation in the UK press and in compliance with UK regulations.
The Neuphoria Board noted that there can be no certainty any agreement will be reached, nor any certainty regarding the terms or whether a transaction will proceed at all. Any further announcements will be made in compliance with applicable SEC and Nasdaq regulations.
Strategic Rationale: Nasdaq Access for Scancell
For Scancell, the strategic value of the proposed transaction appears centered on gaining access to Nasdaq, where specialist biotech investors are deeper and more familiar with late-stage drug development risk, rather than on acquiring Neuphoria's neuropsychiatry pipeline.
Scancell is working to build momentum around its cancer immunotherapy portfolio. Its lead program, iSCIB1+ (search), is being developed for advanced melanoma (search) and is expected to move toward a pivotal Phase III study. The company has also reported early clinical promise for Modi-1, an off-the-shelf cancer vaccine targeting citrullinated peptides.
However, in its latest financial reporting from October 2025, Scancell disclosed that it had only £8.6 million (approximately €10 million) on hand, underscoring the need for fresh capital to finance an expansive Phase III program. In its statement, Scancell indicated that the reverse merger would be associated with possible equity and debt financing to support the global Phase III registrational study for its lead asset.
Neuphoria's Challenges Following Trial Failure
Neuphoria is navigating significant headwinds. The clinical-stage biotechnology company, dedicated to developing therapies for neuropsychiatric disorders, launched a strategic review after its Phase III AFFIRM-1 study of BNC210 in social anxiety disorder (search) missed both its primary and secondary endpoints. The results, announced on October 20, 2025, prompted the company to halt development of BNC210 in that indication.
BNC210 is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor (search), designed as a broad-spectrum anti-anxiety experimental therapeutic intended to restore neurotransmitter balance without the common pitfalls of sedation, cognitive impairment, or addiction.
Despite the setback, Neuphoria is not merely a shell. The company's website still lists BNC210 for post-traumatic stress disorder (search) (PTSD), several early-stage CNS programs, and a strategic partnership with MSD covering two drug candidates in Alzheimer's disease (search) and other central nervous system conditions. Neuphoria's pipeline also includes next-generation α7 nicotinic acetylcholine receptor (search) programs and Kv3.1/3.2 preclinical programs, both in the lead optimization stage.
Scancell's own statement frames the rationale for the potential combination around Nasdaq access and US investor visibility, rather than acquiring a portfolio of CNS drugs.